C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | Semax | Selank |
|---|---|---|
| Type | Approved Outside US | Approved Outside US |
| Regulatory status | Reported Russian approval; not FDA-approved | Reported Russian approval; not FDA-approved |
| Compounding status | Off Category 2, review pending | Off Category 2, review pending |
| FDA-approved indications | None | None |
| Categories | Cognitive & mood | Cognitive & mood |
| Claimed uses |
|
|
| Mechanism | An ACTH-fragment analogue studied for neuroprotective effects and modulation of neurotrophin signaling, including BDNF. Clinical mechanism remains incompletely established. | A tuftsin-derived peptide investigated for anxiolytic effects, with proposed effects on enkephalin metabolism and inhibitory neurotransmission. The mechanism is not fully established in humans. |
| Evidence level | Small/early human studies | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Watch | Watch |
| Routes | Nasal | — |
| WADA | Verify | Verify |
| Where it stands (opinion) | Russian clinical studies report recovery signals, but do not establish cognitive enhancement in healthy people. FDA lists withdrawn nominations with unresolved safety concerns; removal is not clearance. | Small comparative anxiety studies exist. FDA places selank acetate among withdrawn nominations and highlights immunogenicity and inadequate human safety information. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 |